Kai Zheng, PhD, 2016 CBA President Dr. Kai Zheng received his Ph.D. from Department of Pharmaceutical Chemistry at the University of Kansas. After graduation, he joined Pharm. Technical Development department in Genentech at Oceanside, California and focused on formulation development of biotherapeutics at early stage. In 2011, Dr. Zheng joined Late Stage Pharmaceutical Development department in Genentech at South San Francisco site, where he focuses on Phase III and commercial formulation development of biotherapeutics and related regulatory filings. Dr. Zheng was vice president 2015.
He has been a board member and volunteer of Chinese Bioscience Association (CBA) in the last three years. His duty in CBA includes managing CBA membership and helping organizing numerous workshops and annual conferences.
Mark Chen, PhD, 2016 CBA Vice President
Dr. Wenyi Chen, Membership
Dr. Katherine Wang, Treasurer Katherine Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later she discovered that her real interest is in clinical data analysis. She is currently doing statistical programming after she led clinical programming projects at Gilead Sciences for around two years. Previously she worked as certified advanced SAS programmer and data manager as well in Clinovo. Katherine’s diligent work and enthusiasm have been well recognized. She enjoys reading, writing and Scottish Country Dancing.
Dr. Patrick Yang, Alliance Dr. Patrick Yang is currently Principal Scientist at Relypsa, Inc. He has been working in bay area for many years in various pharmaceutical companies in the field of CMC/analytical development. Dr. Yang obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA. He has previously served on CBA board several terms.
Shih-Chen Chang, PhD, Publications (2015 CBA President) Shih-Chen currently worked in Genentech as a senior Real World Data Scientist supporting infectious disease (ID) area since September 2011. Before he joined in the company, he worked at AstraZeneca for ~5 years in global epidemiology department, covering oncology and ID therapeutic areas, and spent 3.5 years for his post-doctorate training on cancer epidemiology at National Cancer Institute. He obtained his PhD in School of Public Health, Johns Hopkins, and Master of Science and Undergraduate degree from National Taiwan University.
Soon after his move to SF Bay area, Shih-Chen participated in his first 2011 CBA annual meeting and joined the CBA Committee board in 2012, supporting publication and sponsorship. He subsequently took the role as vice president in 2013 and chaired the annual conference. Shih-Chen has great passion to serve the community. Looking forward he hopes to continue building the foundation for the growing CBA, and promote this exciting organization to the greater Bay area bioscience communities.
Hui Fang Li, Public relationship
Caesar Ho, Scholarship
Yuan Zhang, Secretary
Mr. Frank Lin, Taiwan Liaison Mr. Frank Lin is the Regional Sales Marketing Director at Specialdeals.com, a VC funded startup a deal-of-the-day website that features discounted gift certificates usable at local or national companies. Frank Lin is the Regional Marketing Director in US and General Manager in Asia Pacific at Matchbin, Inc, a Web 2.0 Content Management System (CMS) provider for newspaper/radio station/magazine industry. Prior to that, Mr. Lin was a Sales Operation / Marketing Specialist at VeriSilicon, a Fabless Semiconductor company. Mr. Lin now is the Marketing Manager at GBC (www.gbc.com.tw). Mr. Lin received his B.A. degree in Electrical and Computer Engineering from Purdue University and an MBA from Santa Clara University.
Mr. Andrew Teng, Taiwan Liaison Currently acting as C.S.O. at Sunwell Scientific Inc. Mr. Teng has more than 16 years of general management experience in the fields of semiconductor and Bio Science. His broad background includes P&L, operational, BD, product development, marketing, IP protection and M&A. He was a Managing Director at Ecos Lab Co. Prior to joining Ecos Lab, Mr. Teng held a senior positions with Encepho Pharmaceutical as V.P. of Business Development. Mr. Teng has extensive international experience having had direct responsibility for business development and strategic planning in Greater China. Mr. Teng has a B.S. degree from San Jose State University. Currently studying PhD in Industrial Economics at Jinan University, China.
Dr. Michelle Chen, Advisor Dr. Chen is a biotech entrepreneur & executive with extensive experience in biopharma, diagnostics and life sciences. She has a track record of successful leadership roles in business development, marketing and R&D. Most recently she was a business development executive at Hoffmann-La Roche responsible for global oncology licensing, collaborations and M&A. Prior to this role, she was involved in the personalized medicine effort for Roche. Dr. Chen started her biotech career in early drug discovery& development at Scios and later Abgenix as a group leader working on the assay development of antibody drugs. She then went on to gain commercial experience at Agilent Technologies and Applied Biosystems respectively. Dr. Chen received a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF and bioinformatics training at Stanford University. She has been a CBA board member, advisor and volunteer in the last five years and a FAST program advisor for BayBio dedicated to help biotech start-ups grow and succeed. She was the president of CBA 2014.
Dr. Lin Sun-Hoffman, Advisor Dr. Sun-Hoffman is a licensed patent attorney and advises on issues related to intellectual property and technology transfer matters. She also consults on biotechnology and pharmaceutical business-related matters. She helps businesses expand into China through providing strategic and practical advice on issues as diverse as government relations, research and/or business partnerships between Chinese and American companies, intellectual property protection and drug regulatory matters. She previously worked for Life Technologies/ABI, BIO, Celera Genomics, US Patent and Trademark Office and National Institutes of Health. She is the former president of Chinese Biopharmaceutical Association based in Washington DC, currently serves on board of US China Green Energy Council, a member of Bayhelix. Dr. Sun-Hoffman has a PhD in Biochemistry/Cell and Molecular Biology. She was the president of CBA 2013.
Shian-Jiun (SJ) Shih, Ph.D. Advisor (CBA Founding President) SJ Shih is a consultant serving pharmaceutical and biotechnology clients, with more than twenty years’ of industrial experience and specializing in assay development and biomarkers.
From 2009 to 2015 she worked at the Translational Medicine Research Centre, Merck Research Laboratories, Merck Sharp & Dohme, most recently as the Director and Site Lead of Molecular Biomarkers and Diagnostics. She lead 29 scientists with broad translational research skills, including immunoassays, nucleic acid-based assays and next generation sequencing, mass spectrometry, flow cytometry, cell-based assays, immunohistory chemistry, and bioinformatics. Her group was responsible for developing clinical biomarker assays to support early phase clinical trials, including those for Keytruda, as well as for collaborating with academic leaders in biomarker discovery, and for building primate disease models for target validation studies.
Prior to joining Merck, she was with Cell Genesys, a biotechnology company developing cell-based immunotherapy and oncolytic adenovirus-based gene therapy products from 2001 to 2008. As the Director of Assay Development there, her group developed quality control and clinical monitoring assays for phase 3 clinical trials, and conducted product characterization studies to answer inquires from FDA, and from regulatory authorities from other countries.
During her time at Bayer Pharmaceuticals (2000-2001), SJ successfully developed liquid parenteral formulations and explored several novel drug delivery routes for biological drugs. From 1994 to 2000 she worked at Aventis (currently Sanofi) in various capacities, including characterization and purification of therapeutic monoclonal antibodies, development of a cell isolation medical device for bone marrow transplantation, liquid formulation and enhanced cellular delivery for gene therapy products. She started her industrial career in 1993 at BioSource (currently Invitrogen) and produced antibody reagents for research and in vitro diagnostic use.
SJ received a BS degree in Chemistry from National Taiwan University, and a Ph.D. in Biochemistry from University of Wisconsin–Madison, and completed her post-doctoral training at the department of Molecular Pharmacology at Stanford University.
Cindy Liu Advisor
Cheni Kwok Advisor
Julie Yang Advisor
Kelley Liu Advisor
Patty Kiang Advisor
Sydney Chen Advisor
Ta-Kai Li Advisor